I love my new ‘Ozempic face' – I look 10 years younger AND I've lost 60lbs – I kept weight off with 2 simple tricks
Exclusive
NO WEIGH I love my new 'Ozempic face' – I look 10 years younger AND I've lost 60lbs – I kept weight off with 2 simple tricks
Some 'skinny jab' users end up looking gaunt, with sunken eyes and cheeks, but Alejandra claims to have de-aged her face and body so much she looks like a teenager
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
13 hours ago
- NBC News
Wegovy use among U.S. teens up 50% as obesity crisis worsens
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug grew 50% last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta. That's up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children aged 12 and older. The average rate climbed further during the first three months of this year, reaching 17.3 new prescriptions per 100,000. That still represents a minute fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and is far slower than the uptake among U.S. adults. 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' said Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system. 'When lifestyle changes alone are insufficient, we need these additional tools.' For its analysis, Truveta reviewed the electronic health records of 1.3 million patients ages 12 through 17. The data covers 30 U.S. health systems with more than 900 hospitals and 20,000 clinics across the country. The analysis did not include other GLP-1 drugs, including Novo's Ozempic and Eli Lilly's LLY.N Zepbound, which are not approved to treat obesity in adolescents, or compounded versions of these therapies. Wegovy became an option to treat adolescents in late 2022 after decades in which the conventional approaches of diet, exercise and counseling largely failed. About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S. government data. Young people with obesity run a much higher risk of developing chronic, costly, life-shortening conditions like type 2 diabetes and cardiovascular and liver diseases. In January 2023, the American Academy of Pediatrics strongly recommended that doctors provide weight-loss drugs to children with obesity starting at age 12. Yet the medical community has not uniformly embraced GLP-1s for adolescents. Some doctors are hesitant because the drugs' long-term safety for children during a critical phase of development is unknown, and the treatments may need to be used indefinitely. Overall, there are limited options for many teens and their parents because insurance plans often do not cover any treatment for obesity, including intensive behavioral counseling, visits with a dietician or the new GLP-1 medications. At Nemours Children's Hospital in Wilmington, Delaware, the Healthy Weight and Wellness Clinic treated about 2,000 adolescent patients last year. About 25% were prescribed Wegovy or another GLP-1 medication, said Dr. Thao-Ly Phan, the clinic's medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023. On average, their patients taking a GLP-1 drug lost 15 pounds (6.8 kg) within 6 to 12 months, and nearly 30 pounds after more than a year. For many of the other patients, the medications were not an option, either because of insurance hurdles or concern within families about potential risks. Other teens opted for lifestyle changes or older, cheaper weight-loss drugs, with some success. 'It is important for us to continue to monitor and better understand outcomes from the medications — both positive and negative — before widespread use,' Phan said. U.S. Health Secretary Robert F. Kennedy Jr. has criticized the idea of prescribing Ozempic or Wegovy widely to children to treat obesity. In a federal health report he released last month, GLP-1 drugs were cited as an example of the 'overmedicalization of our kids.' It noted a lack of 'long-term safety data, raising the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development.' Novo in a statement said semaglutide, the active ingredient in Wegovy and Ozempic, 'did not appear to affect growth or pubertal development' during its clinical trials involving teens. For many adults, Novo said, obesity starts in childhood or adolescence, and 'we are confident in the proven safety and efficacy of our GLP-1 medicines.' Eli Lilly's weight-loss drug Zepbound is in late-stage clinical trials for use by adolescents. Lilly told Reuters that 'there has been no evidence to date suggesting impairment in growth or metabolism' from GLP-1 medications. Dr. Robert Siegel, a pediatrician and director of the Center for Better Health and Nutrition at Cincinnati Children's Hospital, said about 15% of adolescents being treated there were prescribed Wegovy or a similar GLP-1 medication from July 2021 to July 2023. They include patients being treated for type 2 diabetes for which the GLP-1 drugs were originally developed. Siegel said he prefers to start teens on three to six months of intensive lifestyle management before even considering medication. While obesity specialists can help navigate potential risks from the drugs, many primary-care providers need more training, he said. They may not have the equipment to monitor for the loss of muscle mass — a side effect of these medicines — or lack the resources to work with families over an extended period on healthier eating and exercise. 'These medications are likely to be needed for a very long time to maintain weight,' Siegel said, 'and we only have a relatively short-term experience with them.'
Glasgow Times
14 hours ago
- Glasgow Times
‘Hope on the horizon' as drugs assessed for Alzheimer's prevention
Some 138 treatments are being assessed in clinical trials. A third of drugs currently being trialled are 'repurposed' medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia. And four late-stage trials are looking at preventing disease. Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are 'only one part of the overall strategy' as they expressed excitement over the variety of new drugs, which are being tested among patients. The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions. Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: 'This year has really given us real cause for optimism.' She said that as well as more drugs coming through the pipeline, the treatment targets are 'more diverse' and 'looking at all stages of the disease'. She added: 'What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating.' 'This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab.' Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: 'Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia. 'This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments.' James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: 'What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal.' On the drugs which are being investigated for the prevention of disease, Prof Rowe said: 'One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. 'And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today.' He added: 'One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years. 'The ones that are in trial at the moment are really… bringing forward an effective treatment to earlier stage.' For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease. On the repurposing of current drugs, Dr Mead said that it can usually take 10 to 15 years for new drugs to be tested and approved for use. 'Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases,' she said. 'A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment.' Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an 'important first step' in the battle against the disease. The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use. The National Institute for Health and Care Excellence (Nice) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer. Dr Scales added: 'Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease. 'What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and and able to deliver for our patients.' She said studies are showing 'even more complexities' around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have. Dr Richard Oakley, associate director of research at Alzheimer's Society, said: 'This paper shows that 2025 is shaping up to be a landmark year for Alzheimer's disease drug development. 'With more trials under way than ever before and more drugs entering the pipeline, there is hope on the horizon for the nearly one million people living with dementia in the UK.'
Daily Mail
14 hours ago
- Daily Mail
EXCLUSIVE Ozempic shockingly linked to 'silent cancer' that's rising in young people as doctors issue warning
Ozempic and similar weight loss drugs may raise the risk of kidney cancer, a major study suggests. But the fat-melting shots lower the risk of over a dozen other cancers — meaning the benefits may still outweigh the risks. Your browser does not support iframes. Your browser does not support iframes. Your browser does not support iframes.
